<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    15131789
   </pmid>
   <datecreated>
    <year>
     2004
    </year>
    <month>
     05
    </month>
    <day>
     07
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2004
    </year>
    <month>
     06
    </month>
    <day>
     23
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     14
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0016-5085
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       126
      </volume>
      <issue>
       5
      </issue>
      <pubdate>
       <year>
        2004
       </year>
       <month>
        May
       </month>
      </pubdate>
     </journalissue>
     <title>
      Gastroenterology
     </title>
     <isoabbreviation>
      Gastroenterology
     </isoabbreviation>
    </journal>
    <articletitle>
     Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.
    </articletitle>
    <pagination>
     <medlinepgn>
      1287-92
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND &amp; AIMS" nlmcategory="OBJECTIVE">
      Studies that evaluate the risk of hepatotoxicity from statins in hyperlipidemic subjects with elevated baseline serum transaminases are lacking. We conducted a study to test the hypothesis that patients with elevated baseline liver enzymes have higher risk of statin hepatotoxicity.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Our study consisted of the following 3 cohorts of patients seen between January 1, 1998 and June 31, 2002: Cohort 1: 342 hyperlipidemic patients with elevated baseline enzymes (AST &gt;40 IU/L or ALT &gt;35 IU/L) who were prescribed a statin; cohort 2: 1437 hyperlipidemic patients with normal transaminases who were prescribed a statin; and cohort 3: 2245 patients with elevated liver enzymes but who were not prescribed a statin. The effect of statins on liver biochemistries was assessed over a 6-month period after statins were prescribed. Elevations in liver biochemistries during follow-up were categorized into mild-moderate or severe based on predefined criteria.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The incidence of mild-moderate elevations and severe elevations in liver biochemistries in cohort 1 were 4.7% and 0.6%, respectively. Compared with cohort 1, individuals in cohort 2 had lower incidence of mild-moderate elevations (1.9%, P = 0.002) but not severe elevations (0.2%, P = 0.2). However, between cohorts 1 and 3, there were no differences in the incidence of mild-moderate elevations (4.7% vs. 6.4%, respectively, P = 0.2) or severe elevations (0.6% vs. 0.4%, respectively, P = 0.6). Statin discontinuation during the follow-up was similar between cohorts 1 and 2 (11.1% vs. 10.7%, respectively, P = 0.8).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      These data suggest that individuals with elevated baseline liver enzymes do not have higher risk for hepatotoxicity from statins.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Medicine, Indiana University School of Medicine, WD OPW 2005, 1001 West 10th Street, Indianapolis, IN 46202, USA. nchalasa@iupui.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Chalasani
      </lastname>
      <forename>
       Naga
      </forename>
      <initials>
       N
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Aljadhey
      </lastname>
      <forename>
       Hisham
      </forename>
      <initials>
       H
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kesterson
      </lastname>
      <forename>
       Joe
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Murray
      </lastname>
      <forename>
       Michael D
      </forename>
      <initials>
       MD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hall
      </lastname>
      <forename>
       Stephen D
      </forename>
      <initials>
       SD
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <grantlist completeyn="Y">
     <grant>
      <grantid>
       U01 DK 065211
      </grantid>
      <acronym>
       DK
      </acronym>
      <agency>
       NIDDK NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
    </grantlist>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, P.H.S.
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Gastroenterology
    </medlineta>
    <nlmuniqueid>
     0374630
    </nlmuniqueid>
    <issnlinking>
     0016-5085
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hydroxymethylglutaryl-CoA Reductase Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      EC 2.6.1.1
     </registrynumber>
     <nameofsubstance>
      Aspartate Aminotransferases
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      EC 2.6.1.2
     </registrynumber>
     <nameofsubstance>
      Alanine Transaminase
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Gastroenterology. 2004 May;126(5):1477-80
     </refsource>
     <pmid version="1">
      15131809
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Gastroenterology. 2004 Oct;127(4):1278; author reply 1278-9
     </refsource>
     <pmid version="1">
      15481021
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Alanine Transaminase
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aspartate Aminotransferases
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Case-Control Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cohort Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hydroxymethylglutaryl-CoA Reductase Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      poisoning
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hyperlipidemias
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Liver
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      enzymology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Assessment
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2004
     </year>
     <month>
      5
     </month>
     <day>
      8
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2004
     </year>
     <month>
      6
     </month>
     <day>
      24
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2004
     </year>
     <month>
      5
     </month>
     <day>
      8
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     15131789
    </articleid>
    <articleid idtype="pii">
     S0016508504001957
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

